Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 19
B Workshop Agenda Alzheimer’s Diagnostic Criteria Validation: Exploration of Next Steps A Workshop Monday, July 18, 2011 2011 International Conference on Alzheimer’s Disease 10:30 a.m. Session Overview WILLIAM THIES Chief Medical and Scientific Officer Alzheimer’s Association GABRIELLE SILVER Global Strategic Marketing Leader, Neurology GE Healthcare 10:40 a.m. Updating the Diagnostic Criteria: Two Guidelines • eview the primary updates to the criteria R • xamine the similarities and differences between the E National Institute of Aging/Alzheimer’s Association and International Working Group guidelines • iscuss the role the new criteria will have in a clinical D setting PHILLIP SCHELTENS Director Alzheimer Center Vrije Universiteit Medical Center 19
OCR for page 20
20 ALZHEIMER’S DIAGNOSTIC GUIDELINES 11:05 a.m. Validating the New Criteria: Lessons Learned from Cardiovascular Disease and Cholesterol • xplore challenges and lessons learned in the validation E of cholesterol as a biomarker • dentify lessons learned that could be applied in the I validation of AD guidelines ROBERT MAHLEY Senior Investigator Gladstone Institute of Cardiovascular Disease and Neurological Disease University of California, San Francisco 11:45 a.m. Panel Discussion: Identifying Principle Strategies for Validation of New Criteria • dentify a set of core principles that can be used to I validate the newly proposed diagnostic criteria guidelines for symptomatic pre-dementia and dementia AD • iscuss next steps and strategies for moving forward D o Examine the types of studies needed, their design and execution WILLIAM THIES, Moderator Chief Medical and Scientific Officer Alzheimer’s Association MONIQUE BRETELER Professor German Center for Neurodegenerative Diseases DAVID BROOKS Professor, Imperial College Chief Medical Officer, GE Healthcare CHARLES DeCARLI Director Alzheimer’s Disease Center University of California, Davis
OCR for page 21
21 APPENDIX B ROBERT MAHLEY Senior Investigator Gladstone Institute of Cardiovascular Disease and Neurological Disease University of California, San Francisco 12:30 p.m. ADJOURN
OCR for page 22